Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 4/20 | 0.64 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.64 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.50 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.50 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | CASP7 | P55210 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476174 | 0.99 | HSD17B3 (0.74) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL7145361 | 0.96 | HSD17B3 (0.70) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| SCHEMBL10794465 | 0.86 | HSD17B3 (0.73) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| SCHEMBL11097084 | 0.84 | HSD17B3 (0.89) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| SCHEMBL3767036 | 0.84 | HSD17B3 (1.00) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| SCHEMBL10795060 | 0.83 | HSD17B3 (0.86) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| SCHEMBL10791187 | 0.82 | HSD17B3 (0.71) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| SCHEMBL3136947 | 0.82 | HSD17B3 (0.60) | HSD17B3KDM4EGLAGAAALDH1A1 | |
| SCHEMBL29944843 | 0.81 | KDM4E (0.55) | HSD17B3KDM4EGAAALDH1A1HPGD | |
| SCHEMBL7141692 | 0.81 | KDM4E (0.55) | HSD17B3KDM4EGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1413613-B1 | Detectable markers in fixers comprising cationic polymers | HEWLETT PACKARD DEVELOPMENT CO (US) | 2006-08-30 | — | — | EP | claimed |
| US-20050083366-A1 | Detectable markers in cationic polymeric fixers | IU KAI K (US) | 2005-04-21 | — | — | US | claimed |
| US-6830310-B2 | Detectable markers in cationic polymeric fixers | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2004-12-14 | — | — | US | claimed |
| US-20040080557-A1 | Detectable markers in cationic polymeric fixers | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2004-04-29 | — | — | US | claimed |
| EP-1413613-A1 | Detectable markers in fixers comprising cationic polymers | Hewlett-Packard Development Company, L.P. (US) | 2004-04-28 | — | — | EP | claimed |
| EP-1095032-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000004008-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2000-01-27 | — | — | WO | claimed |
| EP-2393801-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| US-9636341-B2 | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-05-02 | — | — | US | disclosed |
| EP-2235008-B1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| US-20150342950-A1 | SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-03 | — | — | US | disclosed |
| US-9150543-B2 | Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N. V. (BE) | 2015-10-06 | — | — | US | disclosed |
| EP-1885710-B1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-19 | — | — | EP | disclosed |
| US-6830310-B2 | Detectable markers in cationic polymeric fixers | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2004-12-14 | — | — | US | disclosed |
| US-20040080557-A1 | Detectable markers in cationic polymeric fixers | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2004-04-29 | — | — | US | disclosed |
| EP-1413613-A1 | Detectable markers in fixers comprising cationic polymers | Hewlett-Packard Development Company, L.P. (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1095032-B1 | REAGENTS FOR CYP2D FLUORESCENT ASSAY | GENTEST CORP (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1095032-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6130342-A | A 2-OXOCHROMAN COMPOUND CONTAINING A QUATERNARY AMINE GROUP | GENTEST CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000004008-A1 | NOVEL CYP2D FLUORESCENT ASSAY REAGENTS | GENTEST CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342950-A1 | SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC2 | GLA 658/4885GAA 953/4885MAOA 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.